Denmark-based Molecular Quantum Solutions (MQS), a company that provides computational tools to accelerate R&D efforts by the pharma, biotech and chemical industry, announced on Thursday that it has secured €600K in a pre-seed round of funding.
MQS says it will use the funds to convert the tool stack they have developed to a SaaS solution for the pharma and chemical sector.
Investors in this round
Joachim Schelde, Investment Associate at Scale Capital, says, “We have been very impressed with their (MQS) product and commercial achievements so far, and sincerely believe that their quantum chemistry simulation platform will disrupt the drug formulation space.”
“We think the company stands out from the competition and that they have a clear value proposition for accelerating the pharma R&D pipeline. We are excited to start the work!,” adds Schelde.
Michael Bjørnlund, Managing Partner of Rockstart Emerging Tech, says, “Increasing computing power will play a pivotal role in tackling global issues and shortcutting its time to market can significantly contribute to worldwide problem-solving.”
“We invested in MQS to streamline computing power and drive change in Industry 4.0 & advanced analytics development. The MQS team works relentlessly to build highly complex quantum chemistry solutions in the space of supercomputing and quantum computing and we’re excited to have joined their journey early on,” adds Bjørnlund.
MQS: Everything you need to know
Founded in 2019 by Mark Nicholas Jones, Molecular Quantum Solutions offers a software platform for computing the thermodynamic characteristics of molecules with applications in the pharmaceutical and chemical sectors.
The company provides computational tools to help pharmaceutical, biotech, and chemical companies expedite their R&D efforts.
Their technologies make use of supercomputers and quantum computing technology, calculating material and chemical properties quickly and effectively using computational models and algorithms.
In the medication formulation and production upscaling phases, pharmaceutical and biopharma industries generally invest between $20B and $60B. Users can now test and analyse novel materials for applications such as batteries, green solvents, medicinal pharmaceuticals, and biodegradable polymers using MQS, eliminating the need for costly laboratory studies.
Mark Nicholas Jones, CEO/CTO of MQS, says, “Over the last three years, we have built a solid infrastructure to run computationally demanding quantum chemistry calculations in the cloud and solve industrial relevant use cases.”
“Further, we have developed novel quantum computing methods which we are integrating into our classical calculation pipeline. We have several collaborations ongoing with quantum computing research institutions and companies. We are now set to push into a worldwide market with our cloud products stack,” he adds.
Rockstart is an early-stage investor that backs creators with a purpose in the fields of energy, agribusiness, and emerging technologies.
By establishing connections between founders and co-investors, mentors, partners, corporations, and other members of the larger Rockstart network, Rockstart invests in early-stage entrepreneurs and gives them access to finance, the market, and experience.
Rockstart has provided capital to more than 300 businesses and its graduates collectively have an estimated value of $1B. Rockstart is a group of more than 45 international specialists that collaborate to help founders with a mission to grow and have a positive influence on the world.
Wercker, Bouw7, iClinic, and 3D Hubs exited Rockstart in 2021.